We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+0.55%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.98B
AUM Growth
+$213M
(+7.7%)
Cap. Flow
+$184M
Cap. Flow
% of AUM
6.16%
Top 10 Holdings %
Top 10 Hldgs %
56.07%
Holding
51
New
12
Increased
15
Reduced
12
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zimmer Biomet
ZBH
|
+$141M |
| 2 |
Johnson & Johnson
JNJ
|
+$90.5M |
| 3 |
AGN
Allergan plc
AGN
|
+$84.8M |
| 4 |
Tenet Healthcare
THC
|
+$76.8M |
| 5 |
Incyte
INCY
|
+$75.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$188M |
| 2 |
BIVV
Bioverativ Inc. Common Stock
BIVV
|
+$136M |
| 3 |
Edwards Lifesciences
EW
|
+$98.6M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$86.3M |
| 5 |
Cardinal Health
CAH
|
+$84.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.08% |
| 2 | Financials | 6.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FPRX
26
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $41.4M | 1.39% |
+1,010,930
| New | +$31.7M |
|
|
27
Edwards Lifesciences
EW
$50B
| $37M | 1.24% |
1,015,470
-2,584,530
| -72% | -$98.6M |
|
|
AGN
28
CALL
DELISTED
Allergan plc
AGN
| $30.7M | 1.03% |
+150,000
| New | +$34.9M |
|
|
CVRS
29
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
| $30.4M | 1.02% |
19,981,655
| – | – |
|
|
MNK
30
CALL
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $29.9M | 1% |
+800,000
| New | +$31.8M |
|
|
31
CALL
Zimmer Biomet
ZBH
$18.4B
| $29.3M | 0.98% |
+257,500
| New | +$29.7M |
|
32
State Street Health Care Select Sector SPDR ETF
XLV
$42.2B
| $28.9M | 0.97% |
353,960
-118,820
| -25% | -$9.54M |
|
33
Intuitive Surgical
ISRG
$126B
| $26.2M | 0.88% |
225,360
-695,412
| -76% | -$75.8M |
|
34
Zoetis
ZTS
$31.9B
| $25.4M | 0.85% |
398,640
+306,306
| +332% | +$19.2M |
|
35
Boston Scientific
BSX
$68.4B
| $20M | 0.67% |
687,170
+233,220
| +51% | +$6.44M |
|
36
Bristol-Myers Squibb
BMY
$132B
| $18.6M | 0.62% |
291,140
-523,980
| -64% | -$30.6M |
|
37
CALL
Sarepta Therapeutics
SRPT
$1.64B
| $10.7M | 0.36% |
+235,000
| New | +$9.39M |
|
38
Pfizer
PFE
$142B
| $8.84M | 0.3% |
+260,939
| New | +$8.39M |
|
|
39
Vertex Pharmaceuticals
VRTX
$122B
| $5.31M | 0.18% |
34,950
-573,476
| -94% | -$86.3M |
|
40
Medtronic
MDT
$110B
| $5.14M | 0.17% |
66,100
-101,330
| -61% | -$8.41M |
|
41
Baxter International
BAX
$13.8B
| – | – |
-65,610
| Closed | -$3.97M |
|
|
42
CALL
Bristol-Myers Squibb
BMY
$132B
| – | – |
-500,000
| Closed | -$27.9M |
|
|
43
Cardinal Health
CAH
$53.2B
| – | – |
-1,084,396
| Closed | -$84.5M |
|
44
Centene
CNC
$30.1B
| – | – |
-865,728
| Closed | -$34.6M |
|
|
HOLX
45
DELISTED
Hologic
HOLX
| – | – |
-1,688,060
| Closed | -$76.6M |
|
46
Eli Lilly
LLY
$1.03T
| – | – |
-327,064
| Closed | -$26.9M |
|
47
Pediatrix Medical
MD
$2.17B
| – | – |
-942,730
| Closed | -$56.9M |
|
48
Puma Biotechnology
PBYI
$402M
| – | – |
-150,000
| Closed | -$13.1M |
|
|
WBA
49
DELISTED
Walgreens Boots Alliance
WBA
| – | – |
-424,350
| Closed | -$33.2M |
|
|
CLVS
50
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
| – | – |
-350,000
| Closed | -$32.8M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q3 2017 Portfolio in Review
As of Q3 2017, HealthCor Management held 51 positions worth $2.98B, up 7.7% from $2.77B the previous quarter. Its ten largest holdings account for 56% of the portfolio.
HealthCor Management deployed $184M of net new capital in Q3 2017, opening 12 new positions and adding to 15 existing holdings. Its largest new stake was Johnson & Johnson: 683,050 shares worth $88.8M.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 90% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Celgene Corp, an estimated $188M trimmed.
- HealthCor Management's largest Q3 2017 buy was Johnson & Johnson: 683,050 shares worth $88.8M.
- HealthCor Management added most to Zimmer Biomet in Q3 2017, an estimated $141M increase.
- HealthCor Management's biggest Q3 2017 reduction was Celgene Corp, cutting an estimated $188M.
- HealthCor Management fully exited Cardinal Health in Q3 2017, selling an estimated $84.5M.
- HealthCor Management's ten largest holdings make up 56% of its $2.98B portfolio in Q3 2017.
- HealthCor Management opened 12 new positions and closed 11 in Q3 2017.
- HealthCor Management's portfolio value rose 7.7% quarter-over-quarter to $2.98B.
Based on HealthCor Management's 13F filing for Q3 2017, filed 14 Nov 2017.